Search results

The paper aims to highlight the growing use of M&A as a strategic tool by companies originating from the emerging markets.

Cross-border mergers play an increasingly important role in the strategies of firms originating from developing countries in expanding their capabilities and expertise within the drug discovery value chain by providing world class service and international business knowledge.

M&A literature is very extensive. However, there is need for more research focusing on M&A activity originating from emerging countries.

This paper aims to review the latest management developments across the globe and pinpoint practical implications from cutting-edge research and case studies.

This briefing is prepared by an independent writer who adds their own impartial comments and places the articles in context.

Acquiring innovation will continue to be a necessity for pharmaceutical companies and to enjoy a sustainable advantage, they have the obligation to look for competitive advantage through coordination between both upstream and downstream capacities. A strict focus on the core competency of the enterprise is fast becoming obsolete.

The paper provides strategic insights and practical thinking that have influenced some of the world’s leading organizations.

The briefing saves busy executives and researchers hours of reading time by selecting only the very best, most pertinent information and presenting it in a condensed and easy-to-digest format.

This paper aims to highlight the growing role of strategic communication in cross-border M&A in helping companies meet market expectations and investor confidence.

Viewpoint.

When all of the elements about a corporation that can possibly be compiled and projected and understood by the financial community, then that company can expect to compete successfully in the capital markets.

Communicating the value of R&D programs and their short/term goals has not been extensively covered for the biotechnology sector.